http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2546656-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96ec3985e3ce9b24614fb87bf51a4f12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2009-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32f65874f3dcca5ef4b8204afda04f0f |
| publicationDate | 2015-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2546656-T3 |
| titleOfInvention | Use of substituted 2,3-dihydroimidazo [1,2-c] quinazolines for the treatment of myeloma |
| abstract | Use of a compound of the general formula: ** Formula ** or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof, in which: R1 represents - (CH2) n- (CHR4) - (CH2) mN (R5) ( R5 '); R2 represents a heteroaryl optionally substituted with 1, 2 or 3 R6 groups; R3 represents alkyl or cycloalkyl; R4 represents hydrogen, hydroxy or alkoxy; and R5 and R5 'can be the same or different and independently represent hydrogen, alkyl, cycloalkylalkyl or alkoxyalkyl, or R5 and R5' can be taken together with the nitrogen atom to which they are attached to form a 3-7 membered nitrogen heterocyclic ring which optionally it contains at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more groups R6 ', or R4 and R5 can be taken together with the atoms to which they are attached to form a nitrogenous heterocyclic ring of 5-6 members optionally containing 1 or more nitrogen, oxygen or sulfur atoms and which may be optionally substituted with 1 or more R6 'groups; Each occurrence of R6 may be the same or different and is independently halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic ring, heterocyclylalkyl, alkyl-OR7, alkyl-SR7, alkyl-N ( R7) (R7 '), alkyl-COR7, -CN, -COOR7, -CON (R7) (R7'), -OR7, -SR7, -N (R7) (R7 '), or - NR7COR7, each of which may be optionally substituted with 1 or more R8 groups; each occurrence of R6 'may be the same or different and is independently alkyl, cycloalkylalkyl or alkyl-OR7; each occurrence of R7 and R7 'may be the same or different and is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heterocyclic ring, heterocyclylalkyl or heteroarylalkyl; Each occurrence of R8 is independently nitro, hydroxy, cyano, formyl, acetyl, halogen, amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heterocyclic ring, heterocyclylalkyl or heteroarylalkyl; n is an integer from 1-4 and m is an integer from 0-4, with the proviso that when R4 and R5 are taken together with the atoms to which they are attached to form a 3-7 membered nitrogen ring, n + m <= 4; for the preparation of a medication for the treatment of multiple myeloma. |
| priorityDate | 2008-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1122.